Project Details
Description
DESCRIPTION (from applicant's abstract) Amyloid-Beta peptide (Abeta) is
considered to be of central importance in the pathogenesis of Alzheimer's
disease (AD); it is known to be neurotoxic, very probably after engagement
to cellular receptors. Such cellular binding sites mediating Abeta effects
on neurons have not hitherto been defined. The applicants have purified to
homogeneity an approximately 55 kDa polypeptide, which interacts with
synthetic Abeta(residues 1-40), and have shown it to be identified to RAGE,
an immunoglobulin superfamily receptor previously found to bind
nonenzymatically glycated adducts of proteins termed advanced glycation
endproducts. Recombinant RAGE bound 125 I-Abeta(1-40 and 25-35), but not
binding to immobilized synthetic Abeta(1-40 or 1-42) or Abeta derived from
AD brain. Binding of 125 I-Abeta to cultured cortical neurons was prevented
by anti-RAGE IgG or excess soluble receptor; in parallel, blocking access to
RAGE prevented Abeta-induced cellular oxidant stress and cytotoxicity.
Increased expression of RAGE in neurons, as well as microglia, near senile
plaques in AD brain underscored the probable relevance of RAGE-Abeta
interaction to AD. The investigators hypothesize that Abeta-induced
perturbation of cellular targets, especially neurons and microglia, is
mediated, at least in part, via interaction with RAGE; initially, this is a
protective mechanism, in which engagement of RAGE by Abeta activates
cellular defenses and, potentially, promotes cellular uptake and degradation
of the peptide. Later, after extensive aggregates of Abeta have formed,
Abeta-RAGE interaction eventuates in cytotoxicity. They propose that
blockage of Abeta-RAGE interaction will attenuate Abeta-induced cellular
oxidant stress and its consequences, including induction of cytokines and
release of toxic mediators, thus, ultimately protecting neurons form
cytotoxicity. The specific aims are (1) to characterize the interaction of
Abeta with RAGE using purified recombinant RAGE and RAGE- bearing cells,
cortical neurons and microglia; and to compare binding of Abeta microglia
RAGE and the macrophage scavenger receptor, the latter a receptor on
microglia shown to interact with Abeta; and (2) to assess if expression of
Macrophage-Colony Stimulating Factor, which they have found to be increased
in cerebrospinal fluid from AD patients, is a consequence of
Abeta-RAGE-mediated neuronal oxidant stress and can be exploited as a
dynamic index of neuronal perturbation and microglial activation in AD.
These studies have the goal of determining if RAGE expressed by neurons and
microglia represents an important cellular target of Abeta in the
pathogenesis of AD.
Status | Finished |
---|---|
Effective start/end date | 8/15/97 → 7/31/00 |
Funding
- National Institute on Aging
ASJC Scopus Subject Areas
- Clinical Neurology
- Neurology
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.